Amiodarone is often recommended as the antiarrhythmic drug of choice for arrhythmia patients with concomitant heart failure. 1 However, in those undergoing cardiac transplantation, the use of amiodarone presents a set of unique challenges. One of these challenges is a metabolic drugdrug interaction with immunosuppressive medications, including cyclosporine and tacrolimus. Additionally, the prolonged half-life of amiodarone is of concern following transplantation given its redistribution into donor myocardial tissues. 1 Whether this results in adverse clinical events after transplantation remains a debate. This systematic review and meta-analysis aimed to evaluate the impact of preimplant amiodarone use on mortality rates following cardiac transplantation.
Commentary
Amiodarone is often recommended as the antiarrhythmic drug of choice for arrhythmia patients with concomitant heart failure. 1 However, in those undergoing cardiac transplantation, the use of amiodarone presents a set of unique challenges. One of these challenges is a metabolic drugdrug interaction with immunosuppressive medications, including cyclosporine and tacrolimus. Additionally, the prolonged half-life of amiodarone is of concern following transplantation given its redistribution into donor myocardial tissues. 1 Whether this results in adverse clinical events after transplantation remains a debate. This systematic review and meta-analysis aimed to evaluate the impact of preimplant amiodarone use on mortality rates following cardiac transplantation.
We searched MEDLINE, SCOPUS, and the Cochrane Central Register of Controlled Trials through February 15, 2016, and proceedings from related conferences over the prior 3 years. Included studies evaluated patients undergoing cardiac transplantation who had received preimplant amiodarone and reported postoperative mortality. The earliest reported mortality rates from each study were included. Outcomes were pooled using a random-effects model producing odds ratios (ORs) and 95% CIs. Statistical heterogeneity was evaluated using the Cochrane Q statistic P value and I 2 value. Publication bias was assessed using Egger's weighted regression statistic. Analyses were performed using Comprehensive Meta-analysis, version 2 (Biostat, Englewood, NJ).
Six studies, with a total of 869 participants, were included. [2] [3] [4] [5] [6] [7] Follow-up times varied between the studies. Two reported in-hospital mortality 4,7 ; 3 reported 1-month mortality 2,3,6 ; and the last had up to 5 years of follow-up (median = 19 months). 5 Use of pretransplant amiodarone was associated with a 2-fold increase in postoperative mortality versus controls (OR = 2.31; 95% CI = 1.19 to 4.50; Figure 1A ). Neither appreciable statistical heterogeneity (I 2 = 23.9%) nor publication bias (Egger's P = 0.66) was observed. Cumulative meta-analysis ( Figure 1B) shows that inclusion of more recent studies stabilizes the effect size, beginning in 2004. To evaluate whether duration of followup was a modifier of mortality, we also conducted a post hoc metaregression. Although a positive trend was seen between longer duration of follow-up and higher odds of mortality with amiodarone use, the association did not reach statistical significance (P = 0.27).
The exact mechanism behind the association seen in our meta-analysis is unclear. One potential explanation includes the higher risk of bradycardia and need for temporary pacing seen with amiodarone use; sinus bradycardia is a known complication following cardiac transplantation and can be exacerbated by amiodarone. Amiodarone also has numerous drug-drug interactions, including with calcineurin inhibitors. This combination could enhance the toxicity of drugs such as tacrolimus and increase patients' risk for electrocardiographic alterations and development of ventricular arrhythmias. Also, the relationship between amiodarone exposure and early graft dysfunction is unclear. Sanchez-Lazaro et al 6 did not see any significant increases in acute graft failure in patients using amiodarone (16%) when compared with those not using amiodarone (23%; P = 0.60). Conversely, a more recent study using propensity-scoring showed higher rates of acute graft failure in patients who had (14%) as compared with those who had not (4.7%; P = 0.01) received amiodarone. 7 Finally, use of amiodarone may serve as a marker of increased risk in sicker patients at increased risk for poor posttransplant outcomes. This effect should be mitigated using multivariable regression and/or propensity-scoring techniques in more modern analyses.
Our meta-analysis suggested that receiving amiodarone prior to cardiac transplantation was associated with a higher rate of postoperative mortality. The differences in follow-up times and observational nature of the studies limit the ability to provide firm conclusions about this potential relationship.
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